IL17A and chronic kidney disease: Another study revealed that adropin treatment in chronic renal failure rat models also decreased renal damage markers such as NGAL (neutrophil gelatinase-associated lipocalin), TIMP-1, IL-17A, IL-33, MMP-2, and MMP-3, while increasing MMP-13 levels (69).